MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer
The purpose of this study is to evaluate the addition of cisplatin to first-line chemotherapy with gemcitabine in elderly patients with non small cell lung cancer in terms of overall survival.
Non-small Cell Lung Cancer Metastatic|Non-small Cell Lung Cancer Stage IIIB
DRUG: Gemcitabine|DRUG: Gemcitabine|DRUG: Cisplatin
overall survival, one year
worst grade toxicity per patient, worst toxicity per patient according to Common Toxicitity Criteria for Adverse Events v. 4.03, at end of each 3 week cycle of chemotherapy|progression free survival, every 9 weeks|quality of life, baseline and 8, 21, 29, and 42 days after therapy initiated|objective response, after 9 and 18 weeks of therapy
The purpose of this study is to evaluate the addition of cisplatin to first-line chemotherapy with gemcitabine in elderly patients with non small cell lung cancer in terms of overall survival.